Zharp2-1_product_DataBase

Bioactivity	Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). Zharp2-1 blocker muramyl dipeptide (MDP) induces growth of mononuclear cells and induces inflammatory cell factor infection. Zharp2-1 attenuates MDP-induced small inguinal peritonitis, or ameliorates by DNBS-induced large inguinal conjunctivitis[1].
Target	RIPK2
Invitro	Zharp2-1 (IC50=6.4-17.4 nM; 2 h) 预处理 THP-1 和 iBMDM 细胞，并抑制 10 μg/mL MDP 或 1 μg/mL L18-MDP 诱导 12 小时后引起的 IL-6 和 TNF-α 释放[1]。 0 --> Zharp2-1 相关抗体:
In Vivo	Zharp2-1（15 mg/kg；灌胃；每天一次，持续 6 天）可保护大鼠免受 DNBS 诱导的结肠缩短和结肠重量增加，保护大鼠免受 DNBS 诱导的腹泻。Zharp2-1 显著改善结肠粘膜结构破坏、肌肉增厚和炎症浸润[1]。药代动力学分析[1]
Name	Zharp2-1
CAS	2772600-18-5
Formula	C19H18N3O2PS
Molar Mass	383.40
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Lai Y, et al. Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease. Biochem Pharmacol. 2023 Aug;214:115647.

PeptideDB